Pediatric Pulmonology Department, University Timone Hospital for Children, AP-HM, Marseille, France.
Pediatric Pulmonology and Allergy Department, Jeanne de Flandre Hospital, CHU Lille, Univ. Lille, Pole Enfant, Lille, France.
Eur J Pediatr. 2022 Aug;181(8):3067-3073. doi: 10.1007/s00431-022-04510-y. Epub 2022 Jun 9.
Early diagnosis of neuroendocrine cell hyperplasia of infancy (NEHI) is crucial as, conversely to the other causes of intersititial lung disease, corticosteroids are not recommended. Diagnosis is historically based on lung biopsy (NEHI), but in current practice, a clinical and radiological approach is more and more preferred (NEHI syndrome). This national study aimed to address diagnosis and initial management of patients followed up for a NEHI pattern in pediatric centers for rare lung diseases (RespiRare, France). Data on neonatal and familial events, symptoms at diagnosis, explorations performed and results, and therapeutic management were collected by questionnaire. Fifty-four children were included (boys 63%). The mean onset of symptoms was 3.8 ± 2.6 months. The most frequent symptoms at diagnosis were tachypnea (100%), retraction (79.6%), crackles (66.7%), and hypoxemia (59.3%). The mean NEHI clinical score, evocative when ≥ 7/10, was 7.9 ± 1.4 (76% with a score ≥ 7). All chest CT-scans showed ground glass opacities evolving at least the middle lobe and the lingula. Lung biopsy was performed in 38.9% of the cases and was typical of NEHI in only 52.4%, even when the clinical presentation was typical. Initial treatments were oxygen (83.6%) and more curiously intravenous pulses of steroids (83.3%) and azithromycin (70.2%).
This national cohort of patients underlines diagnosis difficulties of NEHI. A composite clinical and radiological score should help clinicians for limiting the use of anti-inflammatory drugs.
•Neuroendocrine cell hyperplasia of infancy (NEHI) is an interstitial lung disease whose diagnosis is essential to limit corticosteroids therapy.
•In this national cohort of 54 patients with a NEHI pattern, diagnosis is mainly based on clinical symptoms and chest CT-scan results. The newly proposed clinical score and, when performed, the lung biopsies are faulted in 25 and 50% of the cases, respectively. •Corticosteroids are widely used. Such results plead for a new composite score to formally diagnose NEHI.
本研究旨在探讨法国罕见肺病儿科中心(RespiRare)收治的以神经内分泌细胞增生症(NEHI)模式为特征的患儿的诊断和初始治疗方法。
通过问卷调查收集新生儿和家族史事件、诊断时的症状、进行的检查和结果以及治疗管理的数据。
共纳入 54 例患儿(男 63%),症状平均出现于 3.8±2.6 月龄。诊断时最常见的症状为呼吸急促(100%)、肋间隙凹陷(79.6%)、哮鸣音(66.7%)和低氧血症(59.3%)。提示 NEHI 的临床评分(≥7/10 时为阳性)平均为 7.9±1.4(76%为 7 分以上)。所有胸部 CT 扫描均显示磨玻璃影,至少累及中叶和舌叶。38.9%的患儿进行了肺活检,仅 52.4%的患儿活检结果为典型的 NEHI,即使临床表现典型也是如此。初始治疗为吸氧(83.6%),更令人惊讶的是静脉用类固醇(83.3%)和阿奇霉素(70.2%)。
本研究中,来自法国的这一患儿队列凸显了 NEHI 的诊断困难。综合临床和影像学评分有助于临床医生限制抗炎药物的使用。
神经内分泌细胞增生症(NEHI)是一种间质性肺病,其诊断对于限制皮质类固醇的使用至关重要。
在这一以 NEHI 模式为特征的全国性患儿队列中,诊断主要基于临床症状和胸部 CT 扫描结果。新提出的临床评分和(如果进行)的肺活检在 25%和 50%的病例中存在缺陷。皮质类固醇的应用广泛。这些结果表明需要一种新的综合评分来正式诊断 NEHI。